Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers
Jennifer Shah, Dana Pueschl, Bradley Wubbenhorst, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair
Minah Kim, Banseok Kim, Ji‐Hyeon Jeon, et al.
Molecular Medicine (2025) Vol. 31, Iss. 1
Open Access | Times Cited: 1
Consensus Clustering Analysis Based on Enhanced-CT Radiomic Features: Esophageal Squamous Cell Carcinoma patients’ 3-Year Progression-Free Survival
Jianye Jia, Ziyan Liu, Fen Wang, et al.
Academic Radiology (2024) Vol. 31, Iss. 7, pp. 2807-2817
Closed Access | Times Cited: 7
The AnnotSV webserver in 2023: updated visualization and ranking
Véronique Geoffroy, Jean-Baptiste Lamouche, Thomas Guignard, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. W1, pp. W39-W45
Open Access | Times Cited: 11
Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
Dylane Wineland, Anh N. Le, Ryan Hausler, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 10
Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer
Carly J. Weddle, Malorie Blancard, Nnamdi Uche, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers
Sarah C. Moser, Jos Jonkers
Cancer Discovery (2025) Vol. 15, Iss. 3, pp. 461-480
Closed Access
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
Stefania Morganti, Brittany L. Bychkovsky, Philip D. Poorvu, et al.
The Oncologist (2023) Vol. 28, Iss. 7, pp. 565-574
Open Access | Times Cited: 9
NBBC: a non-B DNA burden explorer in cancer
Qi Xu, Jeanne Kowalski
Nucleic Acids Research (2023) Vol. 51, Iss. W1, pp. W357-W364
Open Access | Times Cited: 8
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
Emma Zattarin, Ida Taglialatela, Riccardo Lobefaro, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 190, pp. 104109-104109
Closed Access | Times Cited: 6
<em>BRAC1</em> & <em>BRCA2</em> Methylation as a Prognostic and Predictive Biomarker in Cancer: Implementation in Liquid Biopsy in the Era of Precision Medicine
Μαρία Παναγοπούλου, Theodoros Panou, Αναστάσιος Γκουντάκος, et al.
(2024)
Open Access | Times Cited: 1
BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine
Μαρία Παναγοπούλου, Theodoros Panou, Αναστάσιος Γκουντάκος, et al.
Clinical Epigenetics (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
KaryoTap Enables Aneuploidy Detection in Thousands of Single Human Cells
Joseph C. Mays, Sally Mei, Manjunatha Kogenaru, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
Giuseppina Raspaglio, Marianna Buttarelli, Natalia Cappoli, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2361-2361
Open Access | Times Cited: 2
Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation
Anna P. Sokolenko, Elena V. Preobrazhenskaya, Cláudia Marchetti, et al.
Pathobiology (2023) Vol. 91, Iss. 2, pp. 108-113
Closed Access | Times Cited: 1
Identification of mutation-independent BRCA2 protein deficiency expands diagnostics and selection of pancreatic cancer patients for personalized therapy with PARP1 inhibitors
Piotr Chrościcki, Radosław Samsel, Dawid Stępnik, et al.
Research Square (Research Square) (2024)
Closed Access
Sex differences in DNA methylation variations according to ART conception-evidence from the Norwegian mother, father, and child cohort study
Dana Kristjansson, Yunsung Lee, Christian M. Page, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Causal effect between breast cancer and ovarian cancer: a two-sample mendelian randomization study
Cheng Qian, Yan Xing, Wenjun Cheng
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Tumor analysis of BRCA carriers reveals genomic similarities although separated by time
Tal Falick Michaeli, Avital Granit Mizrahi, Batia Azria, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Page 1

Scroll to top